Sex Differences in the Physiological and Behavioral Effects of Chronic Oral Methylphenidate Treatment in Rats by Lisa S. Robison et al.
ORIGINAL RESEARCH
published: 28 March 2017
doi: 10.3389/fnbeh.2017.00053
Frontiers in Behavioral Neuroscience | www.frontiersin.org 1 March 2017 | Volume 11 | Article 53
Edited by:
Nuno Sousa,
University of Minho, Portugal
Reviewed by:
Christina Dalla,
National and Kapodistrian University
of Athens, Greece
Antonio Armario,
Autonomous University of Barcelona,
Spain
*Correspondence:
Panayotis K. Thanos
pthanos@ria.buffalo.edu
Received: 07 September 2016
Accepted: 10 March 2017
Published: 28 March 2017
Citation:
Robison LS, Michaelos M, Gandhi J,
Fricke D, Miao E, Lam C-Y, Mauceri A,
Vitale M, Lee J, Paeng S,
Komatsu DE, Hadjiargyrou M and
Thanos PK (2017) Sex Differences in
the Physiological and Behavioral
Effects of Chronic Oral
Methylphenidate Treatment in Rats.
Front. Behav. Neurosci. 11:53.
doi: 10.3389/fnbeh.2017.00053
Sex Differences in the Physiological
and Behavioral Effects of Chronic
Oral Methylphenidate Treatment in
Rats
Lisa S. Robison 1, Michalis Michaelos 1, Jason Gandhi 1, Dennis Fricke 2, Erick Miao 1,
Chiu-Yim Lam 1, Anthony Mauceri 1, Melissa Vitale 1, Junho Lee 1, Soyeh Paeng 1,
David E. Komatsu 3, Michael Hadjiargyrou 4 and Panayotis K. Thanos 2*
1Department of Psychology, Stony Brook University, Stony Brook, NY, USA, 2 Research Institute on Addictions, University at
Buffalo, Buffalo, NY, USA, 3Department of Orthopedics, Stony Brook University, Stony Brook, NY, USA, 4Department of Life
Sciences, New York Institute of Technology, Old Westbury, NY, USA
Methylphenidate (MP) is a psychostimulant prescribed for Attention Deficit Hyperactivity
Disorder. Previously, we developed a dual bottle 8-h-limited-access-drinking-paradigm
for oral MP treatment of rats that mimics the pharmacokinetic profile of treated patients.
This study assessed sex differences in response to this treatment. Male and female
Sprague Dawley rats were assigned to one of three treatment groups at 4 weeks of
age (n = 12/group): Control (water), low dose (LD) MP, and high dose (HD) MP. Rats
drank 4 mg/kg MP (LD) or 30 mg/kg MP (HD) during the first hour, and 10 mg/kg (LD) or
60 mg/kg MP (HD) for the remaining 7 h each day. Throughout 3 months of treatment,
rats were monitored for body weight, food intake, and fluid intake; as well as tested for
open field behavior, circadian activity, novel object recognition, and social interaction.
Chronic MP treated rats exhibited reduced fluid intake during distinct treatment weeks
to a greater extent in males, and reduced total fluid intake in males only. HDMP treatment
decreased body weight in both sexes, while HDMP increased total food intake in females
only, likely to offset energy deficits resulting from MP-induced hyperactivity. LD and HD
MP increased locomotor activity in the open field, particularly in females and during
later treatment weeks. MP dose-dependently increased activity during the dark cycle of
circadian testing in females, while in males hyperactivity was only exhibited by HD rats.
HD MP increased center activity to a greater extent in males, while MP increased rearing
behavior in females only. MP had no effect on social behavior or novel object recognition
in either sex. This study concludes that chronic oral MP treatment at clinically-relevant
dosages has significant effects on food intake, body weight, open field behavior, and
wake cycle activity. Particularly marked sex differences were apparent for locomotor
activity, with females being significantly more sensitive to the hyperactivating effects of
the drug. These findings suggest that chronic MP exposure beginning in adolescence
can have significant behavioral effects that are both dose- and sex-dependent, and raise
concerns regarding the reversibility of these effects post-discontinuation of treatment.
Keywords: methylphenidate, ritalin, psychostimulant, attention deficit hyperactivity disorder, sensitization, sex
differences
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INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD), with
typical symptoms of inattention, hyperactivity, and impulsivity
beginning in childhood, is one of the most frequently diagnosed
neuropsychiatric disorders. Diagnosis rates of ADHD have
jumped to ∼11% of school-aged children in the United States,
an increase of over 40% during the last decade (Visser et al.,
2014). Approximately two-thirds of these individuals are treated
with psychostimulants such as methylphenidate (MP), which are
also used illicitly as a study aid among high school and college
students and abused recreationally (McCabe et al., 2006; Teter
et al., 2006; Wilens et al., 2008). Concern has arisen about the
use of MP during critical periods of neurodevelopment, such
as adolescence, when the brain is particularly susceptible to
external stimuli (Spear, 2000; Dahl, 2004). During this stage
of development, the brain undergoes numerous changes in
regions such as the prefrontal cortex, hippocampus, and limbic
system, including the sprouting and pruning of synapses and
changes in neurotransmitter concentrations and receptor levels
(Rice and Barone, 2000; Spear, 2000; Dahl, 2004; Giedd, 2005).
This presents concerns regarding subsequent effects of MP on
neurobiology, development, and behavior.
In rodents, it has been shown that MP treatment results
in alterations in neurobiology and several types of behavior,
including locomotion, emotional behaviors, cognition, memory,
and responses to natural and drug rewards (Wultz et al., 1990;
Mueller, 1993; Gaytan et al., 1996, 2000; Izenwasser et al., 1999;
Brandon et al., 2001; Heyser et al., 2004; Arnsten and Dudley,
2005; Mague et al., 2005; Berridge et al., 2006; Chuhan and
Taukulis, 2006; Gray et al., 2007; Thanos et al., 2007; Zhu et al.,
2010). A few major caveats exist, however, regarding a majority
of these prior studies. These include issues with treatment
procedures (treatment length and route of administration/dosing
regimen), and a lack of assessment of sex differences in response
to the drug.
Most previous studies on the effects of MP provide treatment
for a few weeks or less. It is estimated that 50–60% of
children and adolescents diagnosed with ADHD have symptoms
that persist beyond childhood, prolonging MP treatment into
adulthood (Mick et al., 2004; Faraone et al., 2008). This
statistic compels research using longer treatment regimens in
animals as well. Moreover, past studies in rodents have utilized
an MP dosing regimen that does not correspond to clinical
dosing (oral doses of 0.25–1 mg/kg MP, resulting in plasma
concentrations of 8–40 ng/mL) (Swanson et al., 1999; Swanson
and Volkow, 2002). Several of these studies injected MP either
subcutaneously or intraperitoneally, which differs significantly
from oral administration, specifically with respect to time to
peak serum concentration, half-life, and rate of elimination
(Kuczenski and Segal, 2001), as well as absolute magnitude and
time course of increases in extracellular DA and locomotor
responses (Gerasimov et al., 2000; Kuczenski and Segal, 2001).
Studies that have used oral dosing have done so by gavage
(Kuczenski and Segal, 2001; Justo et al., 2010), which is stressful
and can cause injury (Brown et al., 2000; Balcombe et al., 2004),
or by administering MP on an oyster cracker or by mixing
with chow (LeBlanc-Duchin and Taukulis, 2007; Zhu et al.,
2010). Although the latter is less stressful and dangerous, oral
administration results in peak serum concentration 15 min post-
administration, and this concentration has been shown to drop
by half within an additional 5 min (Patrick et al., 1984). The
faster metabolism and shorter half-life of MP in rats compared
to humans would therefore necessitate nearly constant dosing
to maintain clinically-relevant plasma concentrations, unlike
previous studies that dosed animals only once or twice per day
(Kuczenski and Segal, 2001; LeBlanc-Duchin and Taukulis, 2007;
Justo et al., 2010; Zhu et al., 2010).
Lastly, most prior studies of MP in animal models have
utilized males only. Although the historical lack of inclusion of
female subjects in scientific research is unfortunately common,
this has also been justified by the apparent gender bias in ADHD,
with lifetime diagnosis rates of males being nearly double that
of females (Bloom et al., 2012). It has been suggested that
differences in diagnosis rates may be at least in part due to
differences in manifestations of symptoms. Whereas, males may
exhibit more observable behavioral issues (hyperactivity and
impulsivity), females may struggle more silently with cognitive
dysfunction (inattention) (Gaub and Carlson, 1997; Gershon and
Gershon, 2002; Biederman et al., 2005). This discovery will likely
increase ADHD diagnosis and subsequent treatment in females
in the coming years, further supporting the need for research
on possible sex differences in response to psychostimulant
treatment. It has been well-documented that females are subject
to different responses to drug treatments due to sex-specific
pharmacological signaling differences, (i.e., growth development
and hormonal distribution) (Brown et al., 2000; Zakharova et al.,
2009; Tingen et al., 2010), and have been shown to be more
sensitive to some of the effects of psychostimulants (Walker
et al., 2001; Carrier and Kabbaj, 2012; Chelaru et al., 2012; Van
Swearingen et al., 2013).
Previously, we developed a dual-bottle 8 h limited-access
drinking paradigm that allowed MP to be consumed voluntarily
in the rats’ drinking water (Thanos et al., 2015). Briefly, In
addition to a water control group, two 8-h-limited-access dosing
regimens were used created: 4 mg/kg MP (low dose; LD) or
30 mg/kg MP (high dose; HD) during the first hour, and 10
mg/kg (LD) or 60 mg/kg (HD) MP from hours two through
eight. In rats, these oral doses were shown to produce plasma
MP concentrations stably within the clinical pharmacokinetic
range (peak at ∼8 ng/mL for the LD and ∼30 ng/mL for the
HD) for an eight to 10 h period (Thanos et al., 2015). Three
months of MP treatment in male rats starting in adolescence
resulted in substantially altered body weight, food intake, open
field behavior, and circadian activity (Thanos et al., 2015). This
study, however, did not examine females to assess possible sex
differences in response to clinically-relevant doses of MP. In
the current study, male and female rats chronically treated with
MP beginning in adolescence were tested for developmental
parameters (body weight, food intake), as well as behavior (open
field locomotor behavior, circadian locomotor activity, social
behavior), and cognitive function (novel object recognition). We
hypothesized that chronic MP treatment would result in sexually
dimorphic effects on physiology and behavior.
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MATERIALS AND METHODS
Animals
Male (n = 36) and female (n = 36) 4 week old Sprague Dawley
rats (Taconic, Hudson, New York USA) were individually housed
in a controlled room (22 ± 2◦C and 40–60% humidity) with a
12 h reverse light-dark cycle (lights off 0800 h). Rats of each sex
were split into three groups (n = 12/group): Control (drinking
only water), low dose MP (LD), or high dose MP (HD). Rats
were treated for 3 months using a previously established dual-
bottle 8-hour limited access drinking paradigm (Thanos et al.,
2015). Rats received 4 mg/kg MP (LD) or 30 mg/kg MP (HD)
during the first hour (09:00–10:00 h), and 10 mg/kg (LD) or
60 mg/kg MP (HD) for the remaining 7 h (10:00–17:00 h).
Purina Lab Diet rat chow was available ad libitum for the entire
experiment, and body weight, food intake, and fluid intake were
recorded daily. All experiments were conducted in conformity
with the National Academy of Sciences Guide for Care and Use of
Laboratory Animals and approved by the Stony Brook University
Institutional Animal Care and Use Committee.
Drugs
Methylphenidate hydrochloride (Sigma Aldrich, St. Louis, MO)
was dissolved in distilled water to produce the 4, 10, 30, and 60
mg/kg solutions for each rat individually, based on body weight
and the average volume of fluid consumed over the previous 3
days.
Procedures
Open Field Test
Animals were run in an open-field arena photo beam activity
monitoring system (Coulbourn Instruments, Allentown, PA) for
90 min to test locomotor activity prior to treatment and once
per week throughout the treatment period. Tests were performed
between 11:00 and 17:00 h. Open field locomotor data was
acquired with Tru Scan v2.0 software, and activity measures
recorded include: (a) distance traveled; (b) velocity; (c) relative
center distance (distance traveled in the center/distance traveled
in the periphery); (d) center time; (e) rearing events; and (f)
rearing time.
Circadian Activity
Rats were tested for circadian locomotor activity over 24 h
during the last week of chronic MP treatment, measured by an
optical beam sensor over their home cages (Minimitter Vital View
software; Bend, Oregon), as has been done in previous studies
assessing behavioral effects of methylphenidate (Thanos et al.,
2015). Beam breaks were recorded and binned by minute, then
summed in two ways: (1) total number of beam breaks per hour,
and (2) total number of beam breaks in the dark (08:00–20:00 h)
and light (20:00–08:00 h) cycles. Throughout circadian activity
testing, food was provided ad libitum, and the 8 h limited access
drinking paradigm was kept in place, with rats having normal
access to water or respective MP solution.
Social Interaction
The social interaction test was performed during the last week
of treatment. Testing procedures were performed in a dimly
illuminated room during the dark cycle between 11:00 and 17:00
h. The social interaction test was conducted in the same arenas as
the weekly locomotor tests. Experimental rats were first placed in
the arenas alone for 5 min for habituation. For female subjects, a
non-experimental female conspecific rat of similar age and body
weight was then placed into the arena with the experimental rat
for 5 min. For male subjects, a 3 week old non-experimental
male rat was placed into the arena with the experimental rat for
5 min. As in a previous study (Lukas et al., 2011), a juvenile
male rat was chosen as a social stimulus because it does not elicit
aggressive behavior by adult male rats. Arenas were thoroughly
wiped down with 10% ammonia between runs to avoid the
influence of olfactory cues from previous rats. Each run was
recorded and later rated by two experimenters blind to treatment
condition. Time spent engaging in active social interaction (i.e.,
grooming, sniffing, following, climbing over, wrestling/boxing)
was recorded for each experimental rat.
Novel Object Recognition
The novel object recognition (NOR) test assessed the rats’ ability
to recognize and distinguish between objects during the last
week of treatment (Ennaceur and Delacour, 1988). Tests were
performed in a dimly illuminated room during the dark cycle
between 11:00 and 17:00 h. The NOR test was conducted in
the same arenas as the weekly locomotor tests, eliminating the
need for habituation to the environment. The NOR test was
set up by placing two identical objects oriented in diagonal
corners of the arena, with each 6 cm from the wall of the
arena. Rats were first placed in the NOR arena for this 5 min
acquisition run. Following a 30 min break in the home cage,
rats were put back in the arena for the 5 min retention run, in
which a novel object replaced one of the initial (i.e., familiar)
objects. Arenas and objects were thoroughly wiped down with
10% ammonia between runs to avoid the influence of olfactory
cues from previous rats. Each run was recorded and time spent
exploring each object was rated by two raters that were blind to
the treatment that each rat received. Exploration was measured
when a rat’s nose physically touched, sniffed, or approached an
object to within two centimeters of the object. Discrimination
was assessed for the retention run using the discrimination
index [DI = (time spent exploring novel object/total exploration
time)–(time spent exploring familiar object/total exploration
time)].
Statistical Analysis
Body weight, food intake, fluid intake, and open field locomotor
activity data were analyzed using three-way repeated measures
ANOVAs [between-subjects factors: Treatment (water, LD MP,
or HD MP) and sex; within-subjects factor: Time (week of
treatment)]. Three-way repeated measures ANOVAs were also
run to analyze circadian activity data [between-subjects factor:
Treatment and sex; within-subjects factor: Time (hour of day or
light cycle)]. A three-way repeated measures ANOVA [between-
subjects factors: Treatment (water, LD MP, or HD MP) and sex;
within-subjects factor: Object (familiar or novel)] was used to
assess time spent interacting with objects in the novel object
recognition test. Two-way ANOVAs (between-subjects factors:
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Treatment and sex) were used to analyze data from the novel
object recognition (discrimination index) and social interaction
tests, as well as total fluid consumption, total food consumption,
and percent change in body weight from pretreatment to the
final week of treatment. When appropriate, follow-up pair-wise
comparisons were performed using the Tukey method. Statistical
significance was set at α = 0.05 for all tests. Two-way ANOVA
statistical tests were run using SigmaPlot 11.0 software, and
three-way repeated measures ANOVA statistical tests were run
using Statistica 8.0 software.
RESULTS
Fluid Intake
Fluid intake was measured daily and averaged weekly for each
treatment group (Figure 1A). A three-way repeated measures
ANOVA revealed that the main effects of treatment [F(2, 66) =
6.49, p < 0.01], sex [F(1, 66) = 47.37, p < 0.001], and time
[F(12, 792) = 256.31, p < 0.001] were significant on fluid
intake. The sex × time [F(12, 792) = 17.08, p < 0.001], and
treatment × time [F(24, 792) = 4.20, p < 0.001] interactions were
also significant, and the treatment × sex interaction was only
marginally significant [F(2, 66) = 2.94, p = 0.060]. Results of
pairwise comparisons can be seen in Table 1. Additionally, the
treatment × sex × time interaction was significant [F(24, 792) =
3.36, p< 0.001]. Male HDMP rats showed decreased fluid intake
in comparison to male water control rats throughout treatment,
as well as decreased consumption compared to LD MP rats
in early treatment weeks. Male LD MP rats showed decreased
fluid intake in comparison to male water control rats in later
treatment weeks. Female HD MP rats showed decreased fluid
consumption in comparison to LD MP and water control female
rats in early treatment weeks; however, fluid consumption in
female HD rats was higher than both other groups in middle
treatment weeks. Female LD MP rats only showed significantly
decreased fluid intake, compared to water control females, in the
first treatment week. Specific pairwise comparisons can be seen
in Table 1.
A two-way ANOVA was run for total fluid consumption
throughout the entire experiment (Figure 1B). The main effects
of treatment [F(2, 66) = 6.488, p< 0.01] and sex [F(1, 66) = 47.374,
p < 0.001] were significant, such that males drank more than
females (p < 0.001) and water treated rats drank more than HD
(p < 0.001) and LD (p < 0.05) MP treated rats. The treatment
× sex interaction approached significance [F(2, 66) = 2.944, p =
0.060], such that HD MP males drank less than both LD MP and
water treated males, while LD MP males drank less than water
treated males (p < 0.05 for all) There were no group differences
in females.
Food Intake
Food intake was measured daily and averaged weekly for each
treatment group (Figure 2A). A three-way repeated measures
ANOVA found that the main effects of sex [F(1, 66) = 434.57,
p < 0.001] and time [F(12, 792) = 556.17, p < 0.001] on food
intake were significant, while themain effect of treatment on food
intake was marginally significant [F(2, 66) = 2.63, p = 0.079].
The sex × time [F(12, 792) = 61.33, p < 0.001] and treatment ×
time [F(24, 792) = 5.72, p < 0.001] interactions were significant,
while the treatment × sex interaction was marginally significant
[F(2, 66) = 2.64, p = 0.078]. Results of pairwise comparisons
can be seen in Table 1. Additionally, the treatment × sex ×
time interaction was significant [F(24, 792) = 3.88, p < 0.001].
HD MP males showed decreased food intake compared to water
controls and LD MP males during early treatment weeks. LD
MP males had greater food intake compared to water control
males in early to mid-treatment weeks. HD MP females had
significantly increased food intake compared to water controls
and LD MP females in some early to mid, and consistently later,
treatment weeks. LD MP females consumed significantly more
FIGURE 1 | (A) Mean (+SEM) daily fluid intake by treatment week. All groups generally increased fluid intake as they grew from adolescents into adults. Males had
greater fluid intake than females. HD male rats drank less than water control rats during treatment weeks 1–5 and 7–12 (*p < 0.05); HD male rats also drank less than
LD rats in treatment weeks 1 and 3 ($p < 0.05); LD male rats drank less than water control rats for treatment weeks 5, 8, 9, 11, and 12 (#p < 0.05). HD female rats
drank less than water control rats in treatment week 1, 3, and 8 (%p < 0.05). HD female rats drank less than LD female rats in week 3, but drank more in weeks 6 and
8 (∧p < 0.05). LD female rats drank less than water control females in week 1 (&p < 0.05). (B) Mean (+SEM) total fluid consumption throughout the entire experiment.
HD MP males drank less than both LD MP ($p < 0.05) and water (*p < 0.05) treated males, while LD MP males drank less than water treated males (#p < 0.05).
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TABLE 1 | Pairwise comparisons of significant main effects of drug and sex, and their interactions over time.
Drug Sex Drug × Sex Drug × Time Drug × Sex × Time
Fluid intake HD & LD < Water M > F M > F (all treatment groups) HD < Water (1–5, 9–12) M: HD < Water (1–5, 7–12)
M: HD & LD < Water HD < LD (1, 3–5) M: LD < Water (5, 8, 9, 11, 12)
LD < Water (1, 5, 8, 11, 12) M: HD < LD (1, 3)
F: HD < Water (1, 3)
F: HD > Water (8)
F: LD < Water (1)
F: HD < LD (3)
F: HD > LD (6, 8)
Food intake LD > Water M > F M > F (all treatment groups) HD < Water (1, 3) M: HD < Water (1)
F: HD > Water HD > Water (9–12) M: HD < LD (1–5)
HD < LD (pre-MP, 1, 3, 4) M: LD > Water (3–5)
HD > LD (12) F: HD > Water (2, 6, 8–12)
LD > Water (pre-MP, 2, 4, 9, 10) F: HD < Water (3)
F: HD > LD (1, 3, 8–12)
F: LD > Water (9, 10)
Body weight HD < Water & LD M > F M > F (all treatment groups) HD < LD & Water (1–12) M: HD < Water (1–12)
HD < LD & Water (M & F) M: HD < LD (2–12)
F: HD < Water (4–12)
F: HD < LD (3–12)
Open field: Distance HD > LD > Water F > M M: HD > Water & LD HD > Water (1–12) M: HD > LD & Water (6, 8-12)
F: HD & LD > Water HD > LD (2–12) F: HD > Water (1–12)
LD & HD: F > M LD > Water (8–12) F: LD > Water (1, 5, 7–12)
F: HD > LD (2–12)
HD: F > M (2–12)
LD: F > M (6–12)
Open field: Velocity HD > LD > Water F > M M: HD > Water & LD HD > Water (1–12) M: HD > Water (6, 8–12)
F: HD > Water & LD HD > LD (2–12) M: HD > LD (6–8, 10–12)
LD: F > M LD > Water (8–12) F: HD > Water (1–12)
HD: F > M F: LD > Water (5, 7–12)
F: HD > LD (2–12)
F: LD < Water (1)
HD: F > M (2–12)
LD: F < M (1)
LD: F > M (5–12)
Open field: Relative center
distance
HD > Water & LD M > F HD > Water & LD (M)
M > F (all treatment groups)
Open field: Center time HD > Water & LD M > F
Open field: Rearing events HD > Water & LD F > M HD > Water & LD (M & F) HD > Water (1-12)
LD: F > M LD > Water (5, 7)
HD: F > M HD > LD (2–12)
F: LD > Water
Open field: Rearing time HD & LD > Water F > M F > M (all drug treatment groups) HD > Water (2–5, 7–12)
F: HD & LD > Water HD > LD (4)
HD < LD (12)
LD > Water (5, 7–9, 11-12)
(Continued)
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TABLE 1 | Continued
Drug Sex Drug × Sex Drug × Time Drug × Sex × Time
Circadian locomotor HD > LD > Water F > M HD > Water (10–18 h) M: HD > Water (16 h)
Activity (Hourly) HD > LD (11, 14–16 h) F: HD > Water (10–18 h), F: HD > LD
(14–18 h)
HD: F > M (17–18 h)
Circadian locomotor HD > LD > Water F > M HD > LD > Water (dark cycle) M: HD > Water (dark cycle)
Activity (by Cycle) M: HD > LD (dark cycle)
F: HD > Water (dark cycle)
F: HD > LD (dark cycle)
F: LD > Water (dark cycle)
HD: F > M (dark cycle)
FIGURE 2 | (A) Mean (+SEM) daily food intake by treatment week. Rats expectedly increased food intake as they grew from adolescents into adults. Males had
greater food intake in comparison to females within all groups of treatment. HD male rats ate less than water control males rats during the first treatment week (*p <
0.05), and ate less than LD rats in treatment weeks 1–5 ($p < 0.05). LD male rats ate more than water control rats for treatment weeks 3–5 (#p < 0.05). HD female
rats ate less than water control female rats in treatment week 3, but ate more in comparison of treatment week 4, 8–12 (%p < 0.05) HD female rats ate less than LD
female rats during treatment weeks 1, 3, 8, 11, and 12 (∧p < 0.05). LD female rats ate more than water control females during treatment weeks 9 and 10 (&p <
0.05). (B) Mean (+SEM) total food consumption throughout the entire experiment, with HD MP females eating more than water treated females (%p < 0.05).
food than water control females during later treatment weeks.
Specific pairwise comparisons can be seen in Table 1.
A two-way ANOVA was run for total food consumption
throughout the entire experiment (Figure 2B). The main effect
of sex was significant [F(1, 66) = 435.734, p < 0.001], such that
males ate more than females (p < 0.001), while the main effect of
treatment was not significant [F(2, 66) = 2.087, p = 0.132]. The
treatment × sex interaction approached significance [F(2, 66) =
2.955, p= 0.059], such that HD MP females ate more than water
treated females (p < 0.05). There were no overall differences in
total food intake between treatment groups in males.
Body Weight
Body weight was measured daily and averaged weekly for each
treatment group (Figure 3). A three-way repeated measures
ANOVA found that the main effects of treatment [F(2, 66) =
47.44, p < 0.001], time [F(12, 792) = 5597.07, p < 0.001], and sex
[F(1, 66) = 1572.94, p< 0.001] on body weight were all significant,
as were the treatment× sex [F(2, 66) = 5.21, p< 0.01], sex× time
[F(12, 792 = 979.83, p< 0.001], and treatment× time [F(24, 792) =
23.48, p < 0.001] interactions. Results of pairwise comparisons
can be seen in Table 1. There was also a significant treatment ×
sex × time interaction [F(24, 792) = 2.59, p < 0.001]. While HD
MP treatment reduced body weight compared to water treatment
in males throughout all treatment weeks; this effect took longer
to appear in females (starting at week 4). HD MP rats of both
sexes also had reduced body weight in comparison to LD MP
rats in all but the first few weeks of treatment. Specific pairwise
comparisons can be seen in Table 1.
A two-way ANOVA was run for percent change in body
weight between the pretreatment period and the final MP
treatment week (Figure 3B). The main effect of treatment was
significant [F(2, 66) = 9.025, p < 0.001], with HDMP rats gaining
less weight than both water (p < 0.001) and LD MP treated
rats (p < 0.01). The main effect of sex was also significant
[F(1, 66) = 284.005, p < 0.001], with males gaining more weight
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FIGURE 3 | (A) Mean (+SEM) body weight by treatment week. Rats expectedly gained weight as they grew from adolescents into adults. Males expectedly gained
more weight than females. HD MP treatment dose-dependently attenuated body weight throughout most of the treatment period. HD male rats weighed significantly
less than water control males (*p < 0.05) and LD males ($p < 0.05) in treatment weeks 1–12. HD MP female rats weighed less than water control females in treatment
weeks 4–12 (%p < 0.05) and less than LD MP female rats in treatment weeks 3–12 (∧p < 0.05). (B) Mean (+SEM) percent change in body weight from pretreatment
to the final week of the experiment. HD MP attenuated weight gain, regardless of sex.
than females throughout the course of the experiment (p <
0.001). The treatment × sex interaction was not significant
(p > 0.05).
Open Field
Rats were run in an open field arena once prior to treatment
and once per week during treatment, assessing horizontal activity
(distance traveled and velocity), center activity (relative center
distance and center time), and rearing activity (rearing events and
rearing time).
Horizontal Activity
Distance traveled data was averaged within treatment groups for
each week (Figure 4A). A three-way repeated measures ANOVA
found that the main effects of treatment [F(2, 66) = 81.219; p <
0.001], sex [F(1, 66) = 52.043; p < 0.001], and time [F(12, 792)
= 45.72; p < 0.001] on distance were significant, as were the
treatment × sex [F(2, 66) = 36.143; p < 0.001], sex × time
[F(12, 792) = 26.334; p < 0.001] and treatment × time ×
interactions [F(24, 792) = 14.685; p < 0.001]. Results of pairwise
comparisons can be seen in Table 1. Additionally, there was
a significant treatment × sex × time interaction [F(24, 792) =
5.686; p < 0.001]. While HD MP treatment increased distance
compared to water treatment in females throughout all treatment
weeks, this treatment effect took longer to appear in males
(starting at week 6). Female HD MP rats also exhibited greater
distance than female LD MP and male HD MP rats in all but the
first week of treatment. Female LDMP rats had significantlymore
distance than female water rats in most treatment weeks, with
this effect being more pronounced during later treatment weeks.
Female LD MP rats exhibited greater distance than male LD MP
rats in mid to late treatment. Specific pairwise comparisons can
be seen in Table 1.
Velocity was averaged within each treatment group for each
treatment week (Figure 4B). A three-way repeated measures
ANOVA reported that the main effects of treatment [F(2, 66) =
78.663; p < 0.001], sex [F(1, 66) = 89.178; p < 0.001], and time
[F(12, 792) = 42.238; p < 0.001] were significant on FP velocity,
as were the treatment × sex [F(2, 66) = 31.506; p < 0.001], sex
× time [F(12, 792) = 40.299; p < 0.001], and treatment × time
[F(24, 792) = 14.584; p < 0.001] interactions. Results of pairwise
comparisons can be seen in Table 1. There was also a significant
treatment× sex x time interaction on velocity [F(24, 792) = 7.793;
p < 0.001]. Female HDMP rats had significantly greater velocity
than female water rats in all treatment weeks and also greater
than female LD MP rats in all but the first week of treatment.
Female LD MP rats had significantly higher velocity than female
water rats in mid to late treatment weeks. Male HD MP rats had
greater velocity than water control and LD MP male rats in mid
to late treatment weeks. Female HD MP rats had greater velocity
than male HDMP rats in all but the first week of treatment, while
female LD MP rats had greater velocity than male LD MP rats in
mid to late treatment weeks. Specific pairwise comparisons can
be seen in Table 1.
Center Activity
Open field runs also assessed center activity. Relative center
distance was averaged within treatment groups for each week
(Figure 5A). A three-way repeated measure ANOVA reported
that themain effects of treatment [F(2, 66) = 5.1749; p< 0.01], sex
[F(1, 66) = 50.6333, p < 0.001], and time [F(12, 792) = 57.0294; p
< 0.001] were significant, as were the treatment× sex [F(2, 66) =
0.7528; p < 0.05] and sex × time [F(12, 792) = 5.8290; p <
0.001] interactions. Male HD MP rats exhibited greater center
activity than male water and LD MP treated rats (p < 0.01 for
both); there were no differences between treatment groups in
females (p > 0.05). The treatment × time and treatment × sex
× time interactions were not significant (p > 0.05). All pairwise
comparisons for significant main effects and interactions can be
seen in Table 1.
Center time was averaged within treatment groups for each
week (Figure 5B). A three-way repeated measure ANOVA
Frontiers in Behavioral Neuroscience | www.frontiersin.org 7 March 2017 | Volume 11 | Article 53
Robison et al. Sex Differences in Methylphenidate Treatment
FIGURE 4 | Horizontal activity in the open field. (A) Mean (+SEM) distance traveled in the open field. There was an overall increase in distance traveled as time
passed. Male HD MP rats exhibited greater activity than male water (*p < 0.05) and LD MP ($p < 0.05) rats in weeks 6 and 8–12. Female LD MP rats traveled a
greater distance than female water rats in weeks 1, 5, 7–12 (&p < 0.05) while female HD MP rats were more active than water rats in all MP treatment weeks (%p <
0.001). Female HD MP rats were also more active than female LD MP rats in weeks 2–12 (∧p < 0.001). Females were more active than males on HD (weeks 2–12,
@p < 0.05) and LD (weeks 6–12, +p < 0.05) MP treatment. Insert graph shows area under the curve by treatment group for all treatment weeks. (B) Mean (+SEM)
velocity in the open field. There was an overall increase in velocity as time passed. Male HD MP rats had greater velocity than water rats in weeks 6, 8, and 10–12 (*p
< 0.05) and greater velocity than LD MP rats in weeks 6–8 and 10–12 ($p < 0.05). Female LD MP rats had significantly greater velocity than female water rats in
weeks 5 and 7–12 (&p < 0.05). Female HD MP rats had significantly greater velocity than female water rats in all MP treatment weeks (%p < 0.001) and also greater
than female LD MP rats in weeks 2–12 (∧p < 0.001). Females moved at a greater velocity than males on HD (weeks 2–12, @p < 0.05) and LD (weeks 5–12, +p <
0.05) MP treatment, although LD MP females moved at a slower velocity water treated females in week 1 (&p < 0.05). Insert graph shows area under the curve by
treatment group for all treatment weeks.
FIGURE 5 | Center activity in the open field. (A) Mean (+SEM) relative center distance. There was an overall increase in center activity as time passed, and over
time males exhibited greater center activity than females. HD MP treatment increased center activity compared to water and LD MP rats in males only. Insert graph
shows area under the curve by treatment group for all treatment weeks. (B) Mean (+SEM) center time in the open field. There was an overall increase in center time as
time passed. Overall, HD MP rats spent more time in the center of the arena than water and LD MP treated rats. Additionally, males exhibited more center time than
females. Insert graph shows area under the curve by treatment group for all treatment weeks.
revealed a significant main effect of treatment on center time
[F(2, 66) = 13.125; p < 0.001], such that HD MP rats spent
more time in the center of the arena than water or LD MP rats.
The main effects of sex [F(1, 66) = 36.391; p < 0.001] and time
[F(12, 792) = 112.330; p < 0.001] were also significant, as was
the sex × time interaction [F(12, 792) = 1.907; p < 0.05)]. The
treatment × sex, treatment × time, and treatment × sex × time
interactions had no significant effect on center time. Results of
pairwise comparisons can be seen in Table 1.
Rearing Activity
The weekly open field runs also measured rearing activity.
Rearing events were averaged within treatment groups for each
week (Figure 6A). A three-way repeated measures ANOVA
reported that the main effects of treatment [F(2, 66) = 45.847;
p < 0.001)], sex [F(1, 66) = 86.198; p < 0.001], and time
[F(12, 792) = 122.943; p < 0.001] were significant, as was
the sex × time interaction [F(12, 792) = 22.521; p < 0.001)].
Results of pairwise comparisons can be seen in Table 1. There
Frontiers in Behavioral Neuroscience | www.frontiersin.org 8 March 2017 | Volume 11 | Article 53
Robison et al. Sex Differences in Methylphenidate Treatment
FIGURE 6 | Rearing activity in the open field. (A) Mean (+SEM) rearing events in the open field. There was an overall increase in rearing events as time passed.
HD rats exhibited more rearing events than both water and LD MP treated rats in both males and females, and throughout most treatment weeks. LD MP increased
rearing events in females only. LD and HD MP treated females exhibited greater rearing events than their male counterparts. Insert graph shows area under the curve
by treatment group for all treatment weeks. (B) Mean (+SEM) rearing time in the open field. There was an overall increase in rearing time as time passed. Females of
all treatment groups exhibited greater rearing time than their male counterparts. LD and HD MP increased rearing time in several weeks, however both MP doses
increased rearing time overall in female rats only. Insert graph shows area under the curve by treatment group for all treatment weeks.
was also a significant treatment × sex interaction on rearing
events [F(2, 66) = 14.410; p < 0.001], such that female LD
and HD MP treated rats had significantly more rearing events
than their male treated counterparts. Male and female HD
MP rats had significantly more rearing events when compared
to their water and LD MP counterparts. Female LD MP rats
also had more rearing events than water-treated counterparts.
The treatment x time interaction effect was also significant on
rearing events [F(24, 792) = 4.282; p < 0.001]. HD MP rats had
significantly more rearing events than water and LD MP rats in
almost all MP treatment weeks. LD MP rats had significantly
more rearing events than water control rats in mid treatment
weeks. Specific pairwise comparisons can be seen in Table 1.
The treatment × sex × time interaction was not significant
(p > 0.05).
Data on rearing time were averaged within treatment groups
for each week (Figure 6B). A three-way repeated measures
ANOVA reported that the main effects of treatment [F(2, 66) =
10.041; p < 0.01], sex [F(1, 66) = 151.907; p < 0.001],
and time [F(12, 792) = 227.980; p < 0.001] were significant,
as was the sex × time interaction [F(12, 792) = 30.986; p
< 0.001)]. Results of pairwise comparisons can be seen in
Table 1. Additionally, there was a significant treatment × sex
interaction [F(2, 66) = 3.805; p < 0.05]. Within females, HD
and LD MP treated rats exhibited increased rearing time
compared to water controls. Females of all treatment groups
also showed increased vertical plane time compared to their
male counterparts. The treatment × time interaction effect was
also significant on rearing time [F(24, 792) = 3.223; p < 0.001].
LD and HD MP treated rats displayed greater rearing time
compared to water treated rats during mid to late treatment,
and throughout treatment, respectively. There was no overall
significant treatment × sex × time interaction on rearing time
(p > 0.05).
Circadian Locomotor Activity
Circadian tests were run during the last week of treatment.
Circadian hourly locomotor activity was measured and averaged
within each treatment group of each sex (Figure 7A). A three-
way repeated measures ANOVA found that the main effects of
treatment [F(2, 66) = 19.0563, p < 0.001], sex [F(1, 66) = 4.2159,
p < 0.05], and time [F(23, 1518) = 188.1059, p < 0.001] were
significant, as were the treatment × time [F(46, 1518) = 9.9712,
p < 0.001], and sex × time [F(46, 1518) = 3.4860, p < 0.001]
interactions. Results of pairwise comparisons can be seen in
Table 1. There was also a significant treatment × sex × time
interaction [F(46, 1518) = 1.9680, p < 0.001]. Within males, HD
MP rats were more active than water treated rats at only one
timepoint in the middle of the dark cycle. Within females, HD
MP rats were more active than water treated rats throughout
most of the dark cycle following MP administration. HD MP
females were also more active than LD MP females from the mid
to late dark cycle. Within HDMP treated rats, females were more
active than males during the last few hours of the dark cycle.
Specific pairwise comparisons can be seen in Table 1.
Circadian light and dark cycle total activity levels were
measured and averaged within each treatment group of each sex
(Figure 7B). A three-way repeated measures ANOVA revealed
that the main effects of treatment [F(2, 66) = 19.0563, p <
0.001], sex [F(1, 66) = 4.2159, p < 0.05], and cycle [F(1, 66) =
544.1540, p < 0.001] were significant, as was the treatment ×
cycle interaction [F(2, 66) = 21.9413, p < 0.001]. Results of
pairwise comparisons can be seen in Table 1. The treatment ×
sex and sex × cycle interactions were not significant (p > 0.05).
Additionally, there was a significant treatment × sex × cycle
interaction [F(2, 66) = 4.8121, p = 0.01]. LD MP rats were more
active than water treated rats during the dark cycle; however,
this was significant for females only (p < 0.01). HD MP rats
were more active than water and LD MP treated rats during the
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FIGURE 7 | Circadian locomotor activity during the last week of treatment. (A) Mean (+SEM) hourly activity over the circadian cycle. A normal circadian cycle
was exhibited by all groups, with no apparent shift in cycle. In females, HD MP treatment resulted in hyperactivity compared to both LD MP (∧p < 0.05) and water
(%p < 0.05) treatment. HD males showed an increase in activity over water control males at 16:00 (*p < 0.05). HD females exhibited more activity in comparison to
HD males at 17:00 to 18:00 (@p < 0.05). (B) Mean (+SEM) total activity throughout the dark cycle. In females, MP dose-dependently increased circadian activity [HD
> Water (%p < 0.05); HD > LD (∧p < 0.05); LD > Water (&p < 0.05)], while in males HD MP increased activity compared to water (*p < 0.05) and LD MP ($p <
0.05) treated rats. Additionally, HD treated females were more active than male HD rats (@p < 0.05).
dark cycle, and this was significant for both males and females
(p < 0.05 for all). Within HD MP treated rats, females were
more active than males during the dark cycle (p < 0.001). There
were no differences between any groups during the light cycle
(p > 0.05).
Social Interaction
Social interaction testing was conducted during the last week of
treatment. The average time spent engaging in social interaction
was calculated for each treatment group. A two-way ANOVA
revealed that there was a significant main effect of sex [F(1, 66) =
151.727, p< 0.001], with females spending more time interacting
with their conspecific than males (p < 0.001). The main effect
of treatment and the treatment × sex interaction were not
significant (p > 0.05). Mean ± SEM for social interaction time
by group: Male water (125.67 ± 10.65), Male LD MP (119.69 ±
9.86), Male HD MP (107.56 ± 9.19), Female water (232.75 ±
6.72), Female LD MP (234.08 ± 7.44), Female HD MP (219.33
± 18.33).
Novel Object Recognition
Novel object recognition testing was conducted during the last
week of treatment. Time spent interacting with the familiar and
novel objects was measured. A three way repeated measures
ANOVA found a significant main effect of object [F(1, 65) =
195.7753, p < 0.001], such that rats spent more time interacting
with the novel object compared to the familiar object (p< 0.001).
The main effect of sex was also significant [F(1, 65) = 12.9599,
p < 0.001], with males spending more time with objects overall
than females (p < 0.001). The main effect of treatment and the
treatment× sex, sex× object, treatment× object, and treatment
× sex× object interactions were not significant (p> 0.05). Mean
± SEM time spent interacting with familiar object: Male water
(20.86± 2.72), Male LD MP (25.56± 5.09), Male HDMP (17.36
± 2.95), Female water (11.41 ± 1.65), Female LD MP (14.29 ±
1.46), Female HD MP (14.33 ± 2.66). Mean ± SEM time spent
interacting with novel object: Male water (57.88± 5.01), Male LD
MP (59.99 ± 7.70), Male HD MP (49.76 ± 4.50), Female water
(42.41 ± 3.98), Female LD MP (49.29 ± 3.73), Female HD MP
(46.33± 4.70).
The time spent interacting with objects was also used to
determine the discrimination index, a ratio of time spent
interacting with the novel vs. familiar object. A two-way ANOVA
revealed that the effects of treatment, sex, and the treatment× sex
interaction were not significant for novel object discrimination
index (p > 0.05). Mean ± SEM for novel object discrimination
index by group: Male water (46.13± 7.23), Male LDMP (47.06±
5.76), Male HD MP (50.64 ± 6.00), Female water (57.33 ± 5.01),
Female LD MP (54.66± 4.18), Female HDMP (53.69± 7.42).
DISCUSSION
Due to the increasing trends of ADHD diagnosis and the use
and abuse of psychostimulants, the current study aimed to
determine the developmental and behavioral effects of chronic
oral MP treatment in male and female Sprague Dawley rats (a
non-ADHD model). Chronic treatment with MP, particularly
with a clinically-relevant high dose, significantly impacted several
measures including food intake, body weight, and locomotor
behavior, with females being significantly more sensitive to
the effects of MP compared to males, despite dosages being
normalized by body weight. These findings have important
clinical implications given the increasing rates of ADHD
diagnosis and treatment and highlight special consideration that
must be given to sex differences in response to being medicated
with psychostimulants.
MP was found to decrease fluid intake in both sexes at
distinct times of treatment. In males, HD treatment attenuated
fluid intake throughout treatment, while LD treatment had
this effect in later weeks of treatment only. In females, MP
treatment attenuated fluid intake only in very early treatment
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weeks. Additionally, MP dose-dependently reduced overall fluid
intake in males (LD: 7.9%; HD: 14.7%). Differences in fluid
intake by the MP-treated rats may be attributable to aversion to
taste or the psychophysiological effects of the drug (assuming
association between consumption and drug effects were made),
or direct effects on thirst; however, the latter is uncorroborated
by prior studies that demonstrate no significant changes in fluid
consumption in response to MP via intraperitoneal injection
(Conners, 1975; Barone et al., 1979; Rajala et al., 2012).
MP treatment reduced food intake in some very early
treatment weeks, which is in agreement with prior studies
(Goldfield et al., 2007; Gray et al., 2007). During later treatment
weeks, however, MP dose-dependently increased food intake in
females, and total food consumption was increased in HD MP
treated females (19.3%). Despite no differences or an increase
in food consumption in MP rats, treatment resulted in an
attenuation of body weight in the HD MP group of both sexes
(males: 15.3%; females: 12.4%). These results are in agreement
with previous studies, which conclude MP treatment elicits a
reduction in body weight (Vanina et al., 2002; Faraone et al.,
2008; Thanos et al., 2015). Reduced body weight despite increased
food intake may be attributable to metabolic effects of stimulants
(Ersche et al., 2013) and/or increases in energy expenditure,
as MP treated rats exhibited increased locomotor activity as
measured by open field and circadian locomotor behavior.
Circadian locomotor activity was assessed over a 24-h period
in the home cage during the last week of MP treatment. HD
MP treatment resulted in increased dark cycle circadian activity
in both males (48%) and females (124%), with a significantly
greater and longer-lasting effect seen in females.When locomotor
behavior was assessed hourly, HD males were only affected
toward the middle to late period of the dark cycle, while HD
MP female rats exhibited increased activity throughout most
of the dark phase. LD MP treatment also increased dark cycle
activity levels in females (45%), which lasted throughout nearly
the entirety of the dark phase, albeit to a lesser a degree than
HD treatment. Activity levels of LD treated males remained
unaffected. These results indicate that the effects of MP are dose-
dependent, with higher doses resulting in greater increases in
dark cycle activity. Additionally, females are more sensitive to
the hyperactivating effects of the drug compared to males, and it
appears that HD treatment in males produces similar locomotor
responses as the LD in females. MP produced no differences in
activity during the light cycle, nor was there a pattern shift of
circadian activity; the only effect of MP seen was an increase in
amplitude of activity during the dark cycle. While concerns have
been presented that psychostimulant treatment may negatively
affect sleep patterns in children and treated patients (Schwartz
et al., 2004; Sangal et al., 2006; Lee et al., 2012), these results agree
with prior studies in rodents and humans that found no effect of
chronic MP treatment on circadian patterns nor multiple other
sleep parameters (Tirosh et al., 1993; Kent et al., 1995; Thanos
et al., 2015).
In agreement with circadian activity results, HDMP treatment
increased measures of horizontal activity (distance traveled and
velocity) in the open field in both sexes. In males, this was
only significant during later weeks of treatment, while females
were affected for the entire duration of treatment. LD MP
treatment also increased these measures of horizontal activity
in females during later weeks of treatment, while males were
unaffected. Within MP treated groups, females were significantly
more active than males; within the HD, this effect was significant
throughout treatment, while in the LD, this effect was significant
during later treatment weeks. While male and female water
treated groups had similar levels of activity, HD MP treated
males (distance: 36%; velocity: 24%) had increased activity to
a similar degree as LD treated females (distance: 52%; velocity:
34%), while activity levels of HD treated females were elevated
well-beyond that (distance: 210%; velocity: 117%). Additionally,
while water treated males and females had consistent levels of
locomotor activity throughout treatment, MP treated animals
(except for LD treated males) showed increasing locomotor
behavior throughout treatment weeks. This finding could be due
to increased sensitivity to the locomotor-activating effects of the
drug over development, or could represent sensitization to MP,
a demonstrated effect of psychostimulant treatment (Kuczenski
and Segal, 2001; Yang et al., 2003), that was clearly most
robust in HD MP treated females. Similar trends to horizontal
open field activity were seen when assessing MP’s effects on
rearing behavior. HDMP treatment resulted in increased rearing
behavior in both males (events: 12%; time: 5%) and females
(events: 63%; time: 24%), while LD MP treatment only increased
this behavior in females (events: 13%; time: 35%). Rearing has
been regarded as a measure of exploratory behavior, and this
finding of MP-induced increases in rearing is in agreement
with prior studies (Hughes, 1972; Hughes and Greig, 1976).
Taken together, these results suggest that females were much
more sensitive to the stimulant effects of MP than males,
demonstrated by greater horizontal activity and rearing behavior.
The results from this study are in agreement with other studies
on sex differences in response to MP and other psychostimulants
that found that females showed greater levels of activity and
exploration in open field than males when given oral MP (van
Haaren and Meyer, 1991; Bethancourt et al., 2011). Females have
generally been shown to be more sensitive to MP than their male
counterparts, a finding that extends to other psychostimulants
such as cocaine (Walker et al., 2001; Carrier and Kabbaj, 2012;
Chelaru et al., 2012; Van Swearingen et al., 2013).
In the open field test, relative center distance was increased
by HD MP in males only (51%); however, as the measure
of relative center distance may be sensitive to overall activity
levels, time spent in the center of the arena was also assessed.
HD MP increased center time similarly in both sexes (males:
25%; females: 19%), while LD treated animals generally showed
no differences in center activity compared to water controls.
Interestingly, MP does not appear to have the same sexually
dimorphic effect on center activity as on other measures of
locomotor behavior. Center activity in the open field has been
used as a measure of anxiety (Fernández-Teruel et al., 1992),
with increased center activity indicating an anxiolytic response.
This interpretation is in agreement with previous studies in rats
finding that MP treatment decreases anxiety in the open field
and other tests, such as the elevated plus maze (Zhu et al.,
2010; Thanos et al., 2015), as well as reports of reduced anxiety
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in clinically-treated ADHD patients (Barrickman et al., 1995;
Bouffard et al., 2003).
While HDMP treatment did reduce social interaction in both
sexes, this effect was not significant. Previous studies have shown
dose-dependent reductions in social play behavior in response
to MP administration (Vanderschuren et al., 2008; Robinson and
Bucci, 2014). There was however, a significant difference between
males and females in our study, with females spending more
time engaging in social interaction. A majority of the literature
does report sex differences in social interaction; however, most
studies found that males are more socially exploratory, and
exhibit less social anxiety, than females as a result of biological
differences (Olioff and Stewart, 1978; Stack et al., 2010; Carrier
and Kabbaj, 2012). One possible explanation for this discrepancy
is that male and female testing utilized different types of social
stimuli. Females were paired with an age- and weight-matched
conspecific, while males were paired with a much younger and
smaller juvenile rat in order to avoid aggression (Van Loo et al.,
2003; Gromov and Voznesenskaya, 2013).
Results showed that all groups exhibited intact object
recognition memory, and that chronic MP treatment had no
effect on degree of exploration of the familiar or novel object.
Known effects of MP on novel object recognition-based memory
are largely mixed. Studies have shown disrupted novel object
exploration as a result of altered recognition memory and/or
reactivity to novel objects in response to MP treatment (Heyser
et al., 2004; Chuhan and Taukulis, 2006). These studies tie
with findings that demonstrate that high concentrations of
catecholamines in the prefrontal cortex impair working memory
(Murphy et al., 1996; Arnsten, 1997). Other studies had shown
therapeutic effects of MP to restore novel objection recognition
in transgenic mice with the DARPP-32 gene, a dopamine
regulated phosphoprotein, knocked out (Heyser et al., 2013).
The lack of effect seen on novel object recognition and social
interaction may reflect the fact that testing was performed while
rats were on MP. Neuroadaptations may have occurred with
long-term treatment that results in normal performance while
on MP.
Further investigation is necessary to determine the
mechanisms driving observed effects and sex differences in
physiological and behavioral responses to MP despite dosages
being normalized to body weight. Important to note is that rats
in this study were single housed out of necessity to accurately
monitor and control treatment dosages. Single housing is a
“deprived” environment, which could have created stress for
the animals and interacted with MP treatment, perhaps in a
sex-dependent way, to contribute to effects on physiology and/or
behavior. Males and females could also exhibit differences in
MP pharmacokinetics, leading to different concentrations of the
drug in the blood and brain. A study in adult rats found that
following a 5 mg/kg injection of MP, brain concentrations of the
drug were consistently higher in females, with a slower rate of
drug clearance (Bentley et al., 2015). A clinical study, however,
found that in individuals receiving 0.3 mg/kg MP orally, women
had lower MP plasma concentrations, yet were more sensitive
to the subjective effects of the drug (Patrick et al., 2007).
Another possibility is that behavioral differences could be due to
previously reported sex differences in catecholamine (particularly
dopamine) neurotransmitter, receptor, and transporter levels in
the brain (Pohjalainen et al., 1998; Andersen and Teicher, 2000;
Lavalaye et al., 2000; Staley et al., 2001). Additionally, clinical
studies have found that males and females differ in the amount
of dopamine released in response to psychostimulants (Munro
et al., 2006; Riccardi et al., 2006). Further studies are necessary
to elucidate the biological mechanisms driving the observed sex
differences in behavioral responses to chronic oral MP treatment.
CONCLUSIONS
With the increasing diagnoses of ADHD and psychostimulant
prescription rates, as well as concern about the illicit use of
MP by both adolescents and adults, there is a need to assess
the possible physiological and behavioral effects of long-term
treatment. Of interest is the investigation of sex differences in the
sensitivity to these effects. The results from this study show that
chronic MP exposure leads to alterations in body weight, food
consumption, locomotor activity, and measures of exploration
and anxiety, with no effect seen on social interaction or novel
object recognition. Females were particularly more sensitive to
the locomotor-activating effects of MP, as well as increases in
exploratory behavior. For these measures, a LD of MP in females
generally had an equivalent effect of HD treatment in males,
despite dosages being normalized for body weight. The HD in
females had an even more pronounced effect, while LD treated
males generally exhibited no difference in behavior compared to
controls. In conclusion, these results provide a critical foundation
for further animal studies to examine the effects of chronic
MP administration. Future studies should aim to determine the
underlying neurobiological mechanisms in MP-induced changes
in behavior, particularly in regards to the sex differences observed
in the current study. Also of interest is to examine whether
behavior is altered following chronic treatment when rats are not
presently on the drug (i.e., during an abstinence period), as this is
of great clinical relevance for adults who were previously treated
with psychostimulants as children.
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